Changing the landscape in
Life-Threatening Diseases

^aRolling New Drug Application submission completed in the first quarter of 2022. ^bDiabetic peripheral neuropathic pain (DPNP). ^cChronic Kidney Disease (CKD). ^dBardoxolone methyl (bardoxolone). On February 25, 2022, we received a Complete Response Letter from the Food and Drug Administration (FDA). We will continue to work with the FDA to confirm our next steps on our Alport syndrome program. Marketing Authorisation Application in Europe is under review. ^eAutosomal Dominant Polycystic Kidney Disease (ADPKD). ^fAYAME study conducted in Japan by our strategic collaborator in CKD, Kyowa Kirin Co., Ltd.

Omaveloxolone, bardoxolone methyl, and RTA 901 are investigational drugs. Safety and efficacy have not been established by any agency.